002038 双鹭药业
已收盘 10-12 15:00:00
资讯
新帖
简况
双鹭药业(002038)披露获得伊布替尼胶囊药品注册证书的公告,10月12日股价下跌2.6%
证券之星 · 10-12 23:06
双鹭药业(002038)披露获得伊布替尼胶囊药品注册证书的公告,10月12日股价下跌2.6%
双鹭药业(002038.SZ)获得盐酸溴己新口服溶液药品注册证书
智通财经 · 10-12 17:53
双鹭药业(002038.SZ)获得盐酸溴己新口服溶液药品注册证书
股市必读:双鹭药业新发布《北京双鹭药业股份有限公司第九届董事会第十二次会议决议公告》
证券之星 · 09-28
股市必读:双鹭药业新发布《北京双鹭药业股份有限公司第九届董事会第十二次会议决议公告》
双鹭药业(002038)2026年中报简析:净利润同比下降310.72%
证券之星 · 08-27
双鹭药业(002038)2026年中报简析:净利润同比下降310.72%
双鹭药业(002038)6月30日股东户数7.41万户,较上期增加17.73%
证券之星 · 08-26
双鹭药业(002038)6月30日股东户数7.41万户,较上期增加17.73%
8月24日双鹭药业(002038)龙虎榜数据:机构净买入201.93万元,北向资金净卖出595.62万元
证券之星 · 08-24
8月24日双鹭药业(002038)龙虎榜数据:机构净买入201.93万元,北向资金净卖出595.62万元
异动快报:双鹭药业(002038)8月24日10点31分触及跌停板
证券之星 · 08-24
异动快报:双鹭药业(002038)8月24日10点31分触及跌停板
双鹭药业:炒股“亏”掉近3亿,主业集采压顶四年下行
新浪证券 · 07-24
双鹭药业:炒股“亏”掉近3亿,主业集采压顶四年下行
双鹭药业(002038)披露关于变更高级管理人员的公告,7月21日股价下跌2.44%
证券之星 · 07-21
双鹭药业(002038)披露关于变更高级管理人员的公告,7月21日股价下跌2.44%
双鹭药业(002038)披露2026年半年度业绩预告,7月15日股价下跌5.11%
证券之星 · 07-15
双鹭药业(002038)披露2026年半年度业绩预告,7月15日股价下跌5.11%
双鹭药业:预计2026年1-6月每股收益亏损:0.24元至0.26元
证券之星 · 07-14
双鹭药业:预计2026年1-6月每股收益亏损:0.24元至0.26元
双鹭药业(002038)披露股票交易异常波动公告,7月13日股价上涨5.33%
证券之星 · 07-13
双鹭药业(002038)披露股票交易异常波动公告,7月13日股价上涨5.33%
异动快报:双鹭药业(002038)7月10日10点2分触及涨停板
证券之星 · 07-10
异动快报:双鹭药业(002038)7月10日10点2分触及涨停板
双鹭药业(002038)披露股票交易异常波动公告,7月1日股价上涨5.9%
证券之星 · 07-01
双鹭药业(002038)披露股票交易异常波动公告,7月1日股价上涨5.9%
7月1日双鹭药业(002038)龙虎榜数据:机构净买入131.54万元(3日),北向资金净卖出1186.8万元(3日)
证券之星 · 07-01
7月1日双鹭药业(002038)龙虎榜数据:机构净买入131.54万元(3日),北向资金净卖出1186.8万元(3日)
异动快报:双鹭药业(002038)6月29日10点10分触及涨停板
证券之星 · 06-29
异动快报:双鹭药业(002038)6月29日10点10分触及涨停板
双鹭药业(002038)披露获得硫酸镁钠钾口服用浓溶液药品注册证书的公告,6月25日股价下跌7.24%
证券之星 · 06-25
双鹭药业(002038)披露获得硫酸镁钠钾口服用浓溶液药品注册证书的公告,6月25日股价下跌7.24%
双鹭药业(002038.SZ)获得达沙替尼片药品注册证书
智通财经 · 06-25
双鹭药业(002038.SZ)获得达沙替尼片药品注册证书
异动快报:双鹭药业(002038)6月23日9点43分触及涨停板
证券之星 · 06-23
异动快报:双鹭药业(002038)6月23日9点43分触及涨停板
双鹭药业(002038)披露2025年年度股东会决议公告,5月29日股价上涨1.2%
证券之星 · 05-29
双鹭药业(002038)披露2025年年度股东会决议公告,5月29日股价上涨1.2%
加载更多
公司概况
公司名称:
北京双鹭药业股份有限公司
所属行业:
医药制造业
上市日期:
2004-09-09
主营业务:
北京双鹭药业股份有限公司的主营业务是基因工程及相关药物的研究开发和生产经营。公司的主要产品是生物、生化药、化学药。公司曾荣获国家科技进步二等奖1项,北京市科技进步一、二、三等奖9项。公司先后九次作为企业独立申请并获国家重大新药创制基金资助。公司是国家火炬计划重点高新技术企业、中关村科技园海淀园首批“百家创新企业”、“北京生物医药产业跨越发展工程”(G20工程)重点培育企业、北京市“知识产权试点单位”和4项国家“863”计划成果的产业化基地。
发行价格:
12.00
{"stockData":{"symbol":"002038","market":"SZ","secType":"STK","nameCN":"双鹭药业","latestPrice":5.61,"timestamp":1791788595000,"preClose":5.76,"halted":0,"volume":17201664,"delay":0,"changeRate":-0.026,"floatShares":852000000,"shares":1027000000,"eps":-0.7041,"marketStatus":"已收盘","change":-0.15,"latestTime":"10-12 15:00:00","open":5.78,"high":5.82,"low":5.59,"amount":97320500,"amplitude":0.0399,"askPrice":5.61,"askSize":795,"bidPrice":5.6,"bidSize":148,"shortable":0,"etf":0,"ttmEps":-0.7041,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791855000000},"marketStatusCode":5,"adr":0,"adjPreClose":5.76,"symbolType":"stock","openAndCloseTimeList":[[1791768600000,1791775800000],[1791781200000,1791788400000]],"highLimit":6.34,"lowLimit":5.18,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1027350000,"isCdr":false,"pbRate":1.2,"roa":"--","roe":"--","epsLYR":-0.34,"committee":0.347489,"marketValue":5763000000,"turnoverRate":0.0202,"status":1,"floatMarketCap":4781000000},"requestUrl":"/m/hq/s/002038","defaultTab":"news","newsList":[{"id":"2674806945","title":"双鹭药业(002038)披露获得伊布替尼胶囊药品注册证书的公告,10月12日股价下跌2.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2674806945","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674806945?lang=zh_cn&edition=full","pubTime":"2026-10-12 23:06","pubTimestamp":1791817577,"startTime":"0","endTime":"0","summary":"截至2026年10月12日收盘,双鹭药业报收于5.61元,较前一交易日下跌2.6%,最新总市值为57.63亿元。北京双鹭药业股份有限公司近日收到国家药品监督管理局核准签发的伊布替尼胶囊《药品注册证书》,药品批准文号为国药准字H20266103,注册分类为化学药品4类。公司已于2025年3月11日递交上市申请并获受理,并作出3类承诺在相关专利期届满后上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101200036250.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002038","BK0188","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674787617","title":"双鹭药业(002038.SZ)获得盐酸溴己新口服溶液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2674787617","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674787617?lang=zh_cn&edition=full","pubTime":"2026-10-12 17:53","pubTimestamp":1791798792,"startTime":"0","endTime":"0","summary":"智通财经APP讯,双鹭药业 发布公告,公司于近日收到国家药品监督管理局核准签发的盐酸溴己新口服溶液《药品注册证书》。盐酸溴己新口服溶液主要适用于成人,青少年和6岁及以上儿童的粘液分泌或粘液清除障碍相关呼吸系统疾病的对症治疗,包括急性支气管炎,气管支气管炎、慢性支气管炎、慢性阻塞性支气管肺部疾病、支气管扩张症、急性鼻窦炎、慢性鼻窦炎。本产品将由公司大兴基地新增生产车间生产。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1505990.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"双鹭药业(002038.SZ)获得盐酸溴己新口服溶液药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002038","BK0239","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670940972","title":"股市必读:双鹭药业新发布《北京双鹭药业股份有限公司第九届董事会第十二次会议决议公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2670940972","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670940972?lang=zh_cn&edition=full","pubTime":"2026-09-28 02:32","pubTimestamp":1790533934,"startTime":"0","endTime":"0","summary":"公司公告汇总北京双鹭药业股份有限公司第九届董事会第十二次会议决议公告北京双鹭药业股份有限公司于2026年9月24日召开第九届董事会第十二次会议,审议通过《关于审议聘任公司2026年度会计师事务所的议案》,拟聘任信永中和会计师事务所为2026年度财务报告和内部控制审计机构;该事项尚需提交公司2026年第一次临时股东会审议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800001285.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002038","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662728869","title":"双鹭药业(002038)2026年中报简析:净利润同比下降310.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662728869","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662728869?lang=zh_cn&edition=full","pubTime":"2026-08-27 06:24","pubTimestamp":1787783089,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理,近期双鹭药业发布2026年中报。根据财报显示,双鹭药业净利润同比下降310.72%。截至本报告期末,公司营业总收入2.51亿元,同比下降17.51%,归母净利润-2.55亿元,同比下降310.72%。按单季度数据看,第二季度营业总收入1.15亿元,同比下降15.68%,第二季度归母净利润-1.69亿元,同比下降325.04%。本文数据来源于双鹭药业2026年中报,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700011627.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002038"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662794754","title":"双鹭药业(002038)6月30日股东户数7.41万户,较上期增加17.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662794754","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662794754?lang=zh_cn&edition=full","pubTime":"2026-08-26 17:41","pubTimestamp":1787737267,"startTime":"0","endTime":"0","summary":"证券之星消息,近日双鹭药业披露,截至2026年6月30日公司股东户数为7.41万户,较6月18日增加1.12万户,增幅为17.73%。在化学制药行业个股中,双鹭药业股东户数高于行业平均水平,截至6月30日,化学制药行业平均股东户数为3.68万户。从股价来看,2026年6月18日至2026年6月30日,双鹭药业区间涨幅为16.73%,在此期间股东户数增加1.12万户,增幅为17.73%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082600039785.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0028","002038"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661220321","title":"8月24日双鹭药业(002038)龙虎榜数据:机构净买入201.93万元,北向资金净卖出595.62万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2661220321","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661220321?lang=zh_cn&edition=full","pubTime":"2026-08-24 18:08","pubTimestamp":1787566100,"startTime":"0","endTime":"0","summary":"证券之星消息,沪深交易所2026年8月24日公布的交易公开信息显示,双鹭药业因日跌幅偏离值达到7%的前5只证券登上龙虎榜。此次是近5个交易日内第2次上榜。截至2026年8月24日收盘,双鹭药业报收于6.37元,下跌10.03%,换手率15.01%,成交量127.91万手,成交额8.43亿元。从龙虎榜公布的当日买卖数据来看,机构合计净买入201.93万元,北向资金合计净卖出595.62万元。深股通专用、沪股通专用为北向资金的交易席位。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400025498.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","002038","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661247313","title":"异动快报:双鹭药业(002038)8月24日10点31分触及跌停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2661247313","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661247313?lang=zh_cn&edition=full","pubTime":"2026-08-24 10:40","pubTimestamp":1787539237,"startTime":"0","endTime":"0","summary":"证券之星8月24日盘中消息,10点31分双鹭药业(002038)触及跌停板。其所属行业化学制药目前下跌。领涨股为键凯科技。该股为民营医院,医美,流感概念热股。8月21日的资金流向数据方面,主力资金净流入5617.82万元,占总成交额13.55%,游资资金净流出2982.6万元,占总成交额7.19%,散户资金净流出2635.21万元,占总成交额6.36%。近5日资金流向一览见下表:双鹭药业主要指标及行业内排名如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400008259.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002038","BK0188","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653408320","title":"双鹭药业:炒股“亏”掉近3亿,主业集采压顶四年下行","url":"https://stock-news.laohu8.com/highlight/detail?id=2653408320","media":"新浪证券","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653408320?lang=zh_cn&edition=full","pubTime":"2026-07-24 17:55","pubTimestamp":1784886900,"startTime":"0","endTime":"0","summary":"北京双鹭药业股份有限公司2026年上半年业绩预告显示,公司预计归母净利润亏损2.51亿元至2.69亿元,而上年同期为盈利1.21亿元,同比下滑逾300%。 这并非双鹭药业首次因金融投资引发业绩剧烈波动。2025年,公司还因一笔理财投资“爆雷”计提减值损失6.11亿元,成为当年巨亏3.47亿元的最大“元凶”。 有市场分析人士指出,双鹭药业利润断崖式下跌的核心原因并非来自药品主业的经营恶化,而是金融资产公允价值变动所致。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-07-24/doc-iniiwzsi1701335.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["002038","BK0239","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653720512","title":"双鹭药业(002038)披露关于变更高级管理人员的公告,7月21日股价下跌2.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653720512","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653720512?lang=zh_cn&edition=full","pubTime":"2026-07-21 22:28","pubTimestamp":1784644119,"startTime":"0","endTime":"0","summary":"截至2026年7月21日收盘,双鹭药业报收于5.59元,较前一交易日下跌2.44%,最新总市值为57.43亿元。近日,北京双鹭药业股份有限公司发布《关于变更高级管理人员的公告》。公司于2026年7月21日召开第九届董事会第十次会议,审议通过聘任魏延锋先生为公司财务负责人,任期至第九届董事会届满之日止。魏延锋先生具备担任财务负责人所需的专业知识和工作能力,未持有公司股份,与主要股东及其他高管无关联关系,未受过监管处罚。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072100044917.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002038","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651145649","title":"双鹭药业(002038)披露2026年半年度业绩预告,7月15日股价下跌5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651145649","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651145649?lang=zh_cn&edition=full","pubTime":"2026-07-15 17:23","pubTimestamp":1784107406,"startTime":"0","endTime":"0","summary":"截至2026年7月15日收盘,双鹭药业报收于6.69元,较前一交易日下跌5.11%,最新总市值为68.73亿元。该股当日开盘6.35元,最高7.33元,最低6.35元,成交额达9.39亿元,换手率为16.19%。北京双鹭药业股份有限公司于2026年7月15日披露《2026年半年度业绩预告》。扣除非经常性损益后的净利润为280万元至400万元,同比下降84.62%至89.23%,主因是主要产品价格下降导致收入减少和毛利率下滑。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500032907.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","002038","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651510118","title":"双鹭药业:预计2026年1-6月每股收益亏损:0.24元至0.26元","url":"https://stock-news.laohu8.com/highlight/detail?id=2651510118","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651510118?lang=zh_cn&edition=full","pubTime":"2026-07-14 22:03","pubTimestamp":1784037788,"startTime":"0","endTime":"0","summary":"证券之星消息,双鹭药业发布业绩预告,预计2026年1-6月每股收益亏损:0.24元至0.26元。双鹭药业2026年一季报显示,一季度公司主营收入1.37亿元,同比下降18.98%;归母净利润-8611.44万元,同比下降287.33%;扣非净利润3269.05万元,同比上升54.62%;负债率12.6%,投资收益4.26万元,财务费用-27.73万元,毛利率63.62%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400049077.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002038","BK0239","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651117157","title":"双鹭药业(002038)披露股票交易异常波动公告,7月13日股价上涨5.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651117157","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651117157?lang=zh_cn&edition=full","pubTime":"2026-07-13 22:15","pubTimestamp":1783952125,"startTime":"0","endTime":"0","summary":"截至2026年7月13日收盘,双鹭药业报收于6.72元,较前一交易日上涨5.33%,最新总市值为69.04亿元。近日,双鹭药业发布《股票交易异常波动公告》。公告显示,公司股票于2026年7月10日、7月13日连续两个交易日收盘价格涨幅偏离值累计超过20%,构成股票交易异常波动。公司、控股股东及实际控制人不存在应披露而未披露的重大事项,且在异常波动期间未买卖公司股票。董事会确认无应披露未披露事项,不存在违反信息公平披露的情形。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300040074.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002038","BK0239","BK0188","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650462905","title":"异动快报:双鹭药业(002038)7月10日10点2分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2650462905","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650462905?lang=zh_cn&edition=full","pubTime":"2026-07-10 10:05","pubTimestamp":1783649130,"startTime":"0","endTime":"0","summary":"证券之星7月10日盘中消息,10点2分双鹭药业(002038)触及涨停板。其所属行业化学制药目前上涨。领涨股为哈药股份。该股为基因编辑,减肥药,肝素概念热股,当日基因编辑概念上涨4.11%,减肥药概念上涨3.34%,肝素概念上涨2.53%。7月9日的资金流向数据方面,主力资金净流出7149.93万元,占总成交额15.12%,游资资金净流入1971.47万元,占总成交额4.17%,散户资金净流入5178.46万元,占总成交额10.95%。近5日资金流向一览见下表:双鹭药业主要指标及行业内排名如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000010690.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002038","BK0188","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648541782","title":"双鹭药业(002038)披露股票交易异常波动公告,7月1日股价上涨5.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648541782","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648541782?lang=zh_cn&edition=full","pubTime":"2026-07-01 22:46","pubTimestamp":1782917176,"startTime":"0","endTime":"0","summary":"截至2026年7月1日收盘,双鹭药业报收于6.28元,较前一交易日上涨5.9%,最新总市值为64.52亿元。近日,双鹭药业发布《股票交易异常波动公告》。公告显示,公司股票于2026年6月29日至7月1日连续三个交易日收盘价格涨幅偏离值累计超过20%,构成股票交易异常波动。公司、控股股东及实际控制人不存在应披露而未披露的重大事项,且在异常波动期间未买卖公司股票。董事会确认目前无任何应披露而未披露事项,不存在违反信息公平披露的情形。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100043672.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002038","BK0028","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648331511","title":"7月1日双鹭药业(002038)龙虎榜数据:机构净买入131.54万元(3日),北向资金净卖出1186.8万元(3日)","url":"https://stock-news.laohu8.com/highlight/detail?id=2648331511","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648331511?lang=zh_cn&edition=full","pubTime":"2026-07-01 17:43","pubTimestamp":1782899032,"startTime":"0","endTime":"0","summary":"证券之星消息,沪深交易所2026年7月1日公布的交易公开信息显示,双鹭药业因连续三个交易日内,涨幅偏离值累计达到20%的证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年7月1日收盘,双鹭药业报收于6.28元,上涨5.9%,换手率9.66%,成交量82.31万手,成交额5.0亿元。从龙虎榜公布的三日买卖数据来看,机构合计净买入131.54万元,北向资金合计净卖出1186.8万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100034035.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","002038","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647342225","title":"异动快报:双鹭药业(002038)6月29日10点10分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2647342225","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647342225?lang=zh_cn&edition=full","pubTime":"2026-06-29 10:15","pubTimestamp":1782699343,"startTime":"0","endTime":"0","summary":"证券之星6月29日盘中消息,10点10分双鹭药业(002038)触及涨停板。其所属行业化学制药目前上涨。领涨股为广生堂。该股为减肥药,创新药,基因编辑概念热股,当日减肥药概念上涨4.37%,创新药概念上涨3.99%,基因编辑概念上涨3.3%。6月26日的资金流向数据方面,主力资金净流出485.89万元,占总成交额2.47%,游资资金净流出324.06万元,占总成交额1.65%,散户资金净流入809.95万元,占总成交额4.11%。近5日资金流向一览见下表:双鹭药业主要指标及行业内排名如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900007891.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002038","BK0188","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646801388","title":"双鹭药业(002038)披露获得硫酸镁钠钾口服用浓溶液药品注册证书的公告,6月25日股价下跌7.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646801388","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646801388?lang=zh_cn&edition=full","pubTime":"2026-06-25 22:53","pubTimestamp":1782399194,"startTime":"0","endTime":"0","summary":"截至2026年6月25日收盘,双鹭药业报收于5.38元,较前一交易日下跌7.24%,最新总市值为55.27亿元。该股当日开盘5.55元,最高5.62元,最低5.23元,成交额达3.35亿元,换手率为7.27%。北京双鹭药业股份有限公司近日收到国家药品监督管理局核准签发的硫酸镁钠钾口服用浓溶液《药品注册证书》,药品批准文号为国药准字H20264944,注册分类为化学药品4类。此次获批将增加公司肠道用药产品储备,但销售受政策、集采及市场环境等因素影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062500044609.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0028","002038"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646879600","title":"双鹭药业(002038.SZ)获得达沙替尼片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2646879600","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646879600?lang=zh_cn&edition=full","pubTime":"2026-06-25 17:47","pubTimestamp":1782380860,"startTime":"0","endTime":"0","summary":"智通财经APP讯,双鹭药业(002038.SZ)发布公告,公司于近日收到国家药品监督管理局核准签发的达沙替尼片(商品名:欣复达®)《药品注册证书》。据悉,达沙替尼是一种酪氨酸激酶抑制剂,主要用于治疗费城染色体阳性(Ph+)的慢性髓细胞白血病(CML)和急性淋巴细胞白血病(Ph+ALL)。它通过阻断癌细胞内异常激酶的信号传导,抑制肿瘤细胞增殖。适用于治疗对甲磺酸伊马替尼耐药,或不耐受的费城染色体阳性(Ph+)慢性髓细胞白血病(CML)慢性期、加速期和急变期(急粒变和急淋变)成年患者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1458753.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"双鹭药业(002038.SZ)获得达沙替尼片药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","002038","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645001572","title":"异动快报:双鹭药业(002038)6月23日9点43分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2645001572","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645001572?lang=zh_cn&edition=full","pubTime":"2026-06-23 09:46","pubTimestamp":1782179207,"startTime":"0","endTime":"0","summary":"证券之星6月23日盘中消息,9点43分双鹭药业(002038)触及涨停板。其所属行业化学制药目前上涨。领涨股为新华制药。该股为化学原料药,医药,创新药概念热股,当日化学原料药概念上涨3.09%,医药概念上涨2.96%,创新药概念上涨2.91%。6月22日的资金流向数据方面,主力资金净流出1536.01万元,占总成交额13.67%,游资资金净流入310.51万元,占总成交额2.76%,散户资金净流入1225.5万元,占总成交额10.91%。近5日资金流向一览见下表:双鹭药业主要指标及行业内排名如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300009884.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0028","002038"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639758636","title":"双鹭药业(002038)披露2025年年度股东会决议公告,5月29日股价上涨1.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2639758636","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2639758636?lang=zh_cn&edition=full","pubTime":"2026-05-29 22:28","pubTimestamp":1780064899,"startTime":"0","endTime":"0","summary":"近日,双鹭药业发布《北京市君泽君律师事务所关于北京双鹭药业股份有限公司2025年年度股东会的法律意见》公告。公告显示,公司2025年年度股东会于2026年5月29日召开,会议由公司董事会召集,采用现场与网络投票相结合的方式举行。北京市君泽君律师事务所出具法律意见书,认为本次股东会的召集、召开程序、出席人员资格、表决程序及表决结果均符合相关法律法规及公司章程的规定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052900046396.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","002038","BK0028"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791844558950,"stockEarnings":[{"period":"1week","weight":-0.0243},{"period":"1month","weight":-0.0053},{"period":"3month","weight":-0.2028},{"period":"6month","weight":-0.3035},{"period":"1year","weight":-0.2227},{"period":"ytd","weight":-0.2375}],"compareEarnings":[{"period":"1week","weight":-0.0117},{"period":"1month","weight":-0.0234},{"period":"3month","weight":-0.0428},{"period":"6month","weight":-0.0571},{"period":"1year","weight":-0.0256},{"period":"ytd","weight":-0.0432}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京双鹭药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"181849人(较上一季度增加145.44%)","perCapita":"4686股","listingDate":"2004-09-09","address":"北京市海淀区阜石路69号碧桐园1号楼4层","registeredCapital":"102735万元","survey":" 北京双鹭药业股份有限公司的主营业务是基因工程及相关药物的研究开发和生产经营。公司的主要产品是生物、生化药、化学药。公司曾荣获国家科技进步二等奖1项,北京市科技进步一、二、三等奖9项。公司先后九次作为企业独立申请并获国家重大新药创制基金资助。公司是国家火炬计划重点高新技术企业、中关村科技园海淀园首批“百家创新企业”、“北京生物医药产业跨越发展工程”(G20工程)重点培育企业、北京市“知识产权试点单位”和4项国家“863”计划成果的产业化基地。","listedPrice":12},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"双鹭药业(002038)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供双鹭药业(002038)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"双鹭药业,002038,双鹭药业股票,双鹭药业股票老虎,双鹭药业股票老虎国际,双鹭药业行情,双鹭药业股票行情,双鹭药业股价,双鹭药业股市,双鹭药业股票价格,双鹭药业股票交易,双鹭药业股票购买,双鹭药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"双鹭药业(002038)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供双鹭药业(002038)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}